Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of fisetin on the proliferation and migration of human breast and cervical cancer cells
Abstract
Purpose: To explore the fisetin effects on the growth, apoptosis, and migration in human breast and cervical cancer cells, MCF-7 and HeLa cells, respectively.
Methods: Cell cycle arrest was used for the determination of cell growth and sulforhodamine B (SRB) colony formation. Gene expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR), while cell migration was assessed by wound healing and matrigel migration assays.
Results: The data indicate that fisetin activated breast and cervical cancer cell death, and this was confirmed by decreased cell growth, changed cell morphology, and arrested cell cycle at G2/M phase. During the incubation period, fisetin inhibited cancer cells at low concentration with half-maximal concentration (IC50) values of 267.10 ± 48.96, 88.42 ± 1.35 and 41.03 ± 8.04 µg/mL after 24, 48 and 72 h, respectively, for MCF-7 cells; and 140.97 ± 22.92, 100.84 ± 10.97 and 95.53 ± 14.33 µg/mL, respectively, for HeLa cells (p < 0.05). Fisetin suppressed the migration of the cancer cells by inhibiting wound healing and suppressing cell migration to the lower chamber. Moreover, fisetin inhibited cancer cells growth by reducing the gene expression of cyclin D1 and cyclin E.
Conclusion: Fisetin reduces cancer cell death, activates apoptosis and suppresses cancer cell migration. Therefore, fisetin is a potential anticancer agent for the prevention and treatment of breast and cervical cancers in humans, but further development studies are required in this regard.
